YMAB Y-Mabs Therapeutics, Inc.

Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody therapeutic products for cancer treatment in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. The company has a license and research collaboration agreement with Memorial Sloan-Kettering Cancer Center. Y-mAbs Therapeutics, Inc. was founded in 2015 and is headquartered in New York, New York.

$32.33  -1.57 (-4.63%)
As of 09/17/2021 15:59:51 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  09/21/2018
Outstanding shares:  43,576,950
Average volume:  169,158
Market cap:   $1,475,079,758
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    984241109
ISIN:        US9842411095
Sedol:      BG31GH0
Valuation   (See tab for details)
PE ratio:   -156.21
PB ratio:   6.30
PS ratio:   39.78
Return on equity:   -18.05%
Net income %:   -114.04%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy